CME vs. Upstart: Which Financial Stock Is a Better Buy for 2027?
The article compares CME Group and Upstart as investment options for 2027. CME Group is a mature, profitable derivatives marketplace with $4 billion in net income, low leverage, and strong free cash flow of $4.2 billion, trading at a lower forward P/E of 25.8. Upstart is a high-growth AI-powered lending platform with 64% revenue growth but carries higher leverage (debt-to-equity of 2.3), negative free cash flow of $166.1 million, and a higher forward P/E of 48.6. The author recommends CME Group for investors seeking stability and dividends, while Upstart appeals to growth-focused investors.